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Abstract This review briefly describes the concerns of nanobiotechnology in the design and development
of novel vaccines using the most known nanocarriers, including nature-made nanocarriers (such as
bacterial spores, virus-like particles, exosomes, and bacteriophages), man-made nanocarriers (such as
Proteosomes, liposomes, virosomes, SuperFluids, and nanobeads), and their applications in therapeutic
and protective immunization, as well as their advantages and disadvantages. Here, we focus on the
development of nano-based vaccines as ‘‘nanovaccines’’ for inducing immune systems, and the foreseeable
promises and problems when compared with existing vaccines. Also, we review a potential nano-hazard
for vaccines, so-called nanobacterial contamination.
© 2013 Sharif University of Technology. Production and hosting by Elsevier B.V. All rights reserved.
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Vaccination is the most effective strategy for reducing high
morbidity and mortality rates, as well as diminishing the enor-
mous social and economic impact associated with disorders.
Vaccines are utilized to stimulate the immune system to initi-
ate an immune response against specific targets, such as cancer
cells andmicrobial agents [1,2]. Various types of vaccinemay be
used to treat cancers, such as whole tumor cell vaccines, den-
dritic cell vaccines, idiotype vaccines, antigen or adjuvant vac-
cines, viral vectors, and DNA vaccines [3–8]. Although the
immunologic effect is not always sufficient to reverse the pro-
gression of cancer, vaccines are generally well tolerated and
provide useful anticancer effects in some situations [9]. Antigen
cancer vaccines are typically composed of a cancer associated
antigen, not normally present on healthy cells, alongwith other
components (i.e. adjuvants) utilized to stimulate the immune
responses against the antigens, resulting in the destruction of
malignant cells, without harming normal cells, and preventing
recurrence [10].
On the other hand, infection can protect against subsequent
disease by induction of both humoral and cellular immunity,
but, inert protein-based vaccines are not as effective [11]. CD8
T cells play a vital role in protective immunity against many in-
tracellular pathogens and cancer, but are notoriously difficult to
activate by vaccination and immunotherapy [12]. Vaccines that
require a specific immunization sequence with repeated doses
(such as prime-boost) are very efficient, but complicated to ad-
minister, where logistic considerations of vaccine distribution
are critical [13].
As a novel approach, simple inert nanocarriers able to gen-
erate strong protection after a single dose could be useful
for a variety of applications [14]. These nanomaterials could
be classified as nature-made and man-made nanocarriers/
nanoparticles. In fact, nanobiotechnology is particularly used
in developing a new generation of more effective vaccines
(i.e., nanovaccines) capable of overcoming the many biologi-
cal, biophysical, and biomedical barriers that the body builds
against standard intervention [15]. Nanoparticles show much
promise in cancer therapy, by selectively gaining access to
tumors, due to their small size and modifiability [16]. Nano-
sized particles have similarly been used for vaccine construc-
tion against microbial agents [17]. Typically, nanoparticles are
defined as particles between 0.1 and 100 nm [18]. Nanopar-
ticles are formulated out of a variety of substances and fabri-
cated to carry an array of substances in a controlled and
targeted mode [19]. Nanocarriers are prepared to take ad-
vantage of fundamental cancer morphologies and modes of
development, such as rapid cellular proliferation, antigen
expression, and leaky tumor vasculature [20]. Additionally,
nanocarriers are promising as the delivery systems for DNA
vaccines [21]. Nanoemulsions or nanosized aerosol vaccines
are also under development [22,23]. Although many reports
have shown that safe, biocompatible materials could be en-
gineered into nanoparticles that contain drugs or vaccines,
researchers are trying to develop new materials for vectors
that interact specifically and predictably with cells. Nanosys-
tems will be designed to evade normal barriers and stimulate
antigen-presenting cells of the immune system [24–26]. Sci-
entists are also looking to these ‘‘smart’’ targetable nanoparti-
cles as magic bullets that could seek out and destroy individual
cancer cells while bypassing healthy ones [27]. Hence, various
types of nano-scaled material have been employed for the de-
sign and fabrication of nanovaccines (Table 1), based on natureor man-made nanocarriers. Bacterial spores, Proteosomes, exo-
somes, liposomes, virosomes, SuperFluids, nanoparticle-based
nanobeads, virus-like particles and bacteriophages are some in-
stances of nano-sized vehicles that are reviewed here as poten-
tial nanocarriers for vaccine delivery to immune systems [28].
Nanobacteria are another important subject for reviewhere, be-
cause of their role in the contamination of vaccines and some
complicated disorders [74]. Because nanobacteria have been
found to be a contaminant in previously assumed-to-be-sterile
medical products, we also aim to discuss it as a nano-hazard in
this review [75].
2. Nature-made nanocarriers
2.1. Bacterial spores
Through evolution, nature has produced highly complex
nanoarchitectures using macromolecules, especially polysac-
charides, nucleic acids, and proteins [76]. Understanding the
principle of how these macromolecules interact to fabricate
nano-scaled structures, it should be possible to exploit this sci-
ence in the design and development of novel artificial struc-
tures and tools [77]. The advantage of this ‘‘learning from
nature’’ approach is that it well defines the bionanofabrication
processes that already exist in bacteria [78]. Microorganisms
have novel and interesting structures, such as bacterial spore
coats [79], which have protective characteristics [80]. Bacterial
spores are dormant life forms with formidable resistance prop-
erties. These nanostructures attribute multiple layers of pro-
tein, which encase the spores in a protective and flexible shell
[81–85]. The shield has features that are pertinent for merging
with nanobiotechnological fields, such as self-assembling pro-
tomers, and a capacity for engineering and delivering foreign
molecules [86]. In fact, the spore coat could be employed not
only as a delivery vehicle for various molecules, but also as a
source of novel self assembling biomolecules [87]. The coat can
act as a device for heterologous antigen presentation and pro-
phylactic immunization [29].
There are a number of attributes that make bacillus spores
particularly suitable candidates for vaccine vehicles [30,31].
Two distinct approaches are accessible for vaccination. In the
first approach, an antigen or epitope is engineered onto the
spore coat by fusing a spore coat gene with the antigen se-
quence [32–34]. In the second, the antigen is expressed con-
stitutively in the vegetative cell by fusion of the antigen gene
to the transcriptional and translational sequences of a suitable
bacillus gene [88–90]. Spores carrying this modified gene are
used for oral delivery and then germinate in the gastrointesti-
nal system [91–93]. Consequently, the spore offers unique capa-
bilities for nanovaccine development that could ultimately lead
to improved public health, both in developed and developing
countries.
2.2. Virus-like particles
Virus-Like Particles (VLPs) structurally mimic the viral cap-
sid, and have been extensively and successfully employed as
nanovaccines [94]. The capability of VLPs to include nucleic
acids and small biomolecules has also made them novel vehi-
cles for gene and vaccine deliveries [95]. The repetitive surface
of VLPs has regularly been used as a template for bionanofab-
rication [96]. Recent progress has been shaped towards the de-
velopment of virus capsids, along with the precise spacing of
surface peptide domains, which enables the modification of
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Nanocarrier Source Size (nm) Immune response Ref. no.
Spore Bacterial Various Humoral-cellular [29–34]
Proteosome Membrane protein-based 20–800 Humoral-cellular [35–41]
Exosome Cellular 50–100 Cellular [42–44]
Liposome Lipid-based Various Humoral-cellular [45–50]
Virosome Liposome+ viral env proteins Various Humoral-cellular [51–54]
SuperFluid Biodegradable polymer 25–250 Humoral-cellular [55–59]
Nanobead Inert nanomaterial 40 Humoral-cellular [60–63]
VLP Viral Various Humoral [64–68]
Phage Bacterial Various Humoral-cellular [69–73]the capsid shield through the fabrication of repetitive chemi-
cal adducts on a nanoscale platform [97]. Recently, capsid en-
gineering has been improved for bacteriophage and plant virus
capsids, with an extension to purified VLPs [98]. VLPs of vari-
ous viruses have been confirmed as very immunogenic and are
already in use as nanovaccines in humans or animals [99]. For
instance, the immunization of young healthy womenwith VLPs
composed of the major structural protein, L1, of HPV16, induced
high titer neutralizing antibodies, andprotected them fromHPV
infection and associated cervical dysplasia [64]. The vaccination
mode decreases the incidence of cervical cancer; however, a
longer follow-up is essential to confirm this action. VLPs have
additionally been employed to deliver immunogenic epitopes
of other pathogens. They have several advantages as immuno-
gens in the form of short peptides [65].
The linking of VLPs to adjuvantmolecules was also shown to
improve the immunogenicity of the nanobioparticles [66]. For
instance, the nontoxic subunit of cholera toxin (CTB)was chem-
ically linked to VLPs via biotin-streptavidin [67]. There was a
higher level of Env-specific serum IgG1, secretory IgA antibod-
ies and cellular immune responses than in either the absence
of CTB or when CTB was just co-injected [68]. As there is in-
creasing awareness of the VLP structure, it is expected that the
development of VLPs as nanovaccines, as carriers for delivering
small molecules, and as the basis for nanoarrays, will continue
with even greater potency [100–102].
2.3. Bacteriophages
While the study of the interaction of phage nanobioparticles
and animals is still in its infancy, the capacity of a few of the
well-studied phage strains to deliver antigenic gene products
has been investigated [103–105]. Phage vaccines introduced
in 1985 showed that it was possible to manufacture bacterio-
phages that display foreign proteins fused to their normal coat
proteins [106]. Following the description of phage display tech-
nology, its power was greatly improved using the affinity se-
lection to isolate phages that displayed specific peptides from
random peptide collections [107–109]. Employment of this
technology for the development of vaccines and diagnostics has
become an industry [110–112]. Additionally, it was also pos-
sible to use specific epitopes that have been chosen on the
basis of biological experiments [113]. For instance, a vaccine
using a phage display system provided complete immunolog-
ical protection to mice nasally challenged with live respira-
tory syncytial virus [114]. A similar approach was applied to
construct a phage carrying a gene product protection against
Yersinia pestisinfections [69]. The phage IgG2 responses were
indicated to be significantly higher following intramuscular
phage vaccinations with the phage vaccine than with the plas-
mid DNA vaccine [70]. Moreover, it was demonstrated thatthe phage nanovaccines might be made more efficient via
decorating their coats with phage fusion proteins displaying
immunogenic antigens for dendritic cells [71]. This could be
accomplished using a peptide that has an attaching epitope for
the CD40 receptor, which has numerous functions in the ac-
tivation of antigen-presenting cells [72]. This requirement for
the peptide display by phage vaccines can be enhanced by ap-
plication of a developed dual expression system that permits
the generation of phages with mosaic heads that can accom-
modate recalcitrant recombinant fusion proteins. This system
employed bacteria carrying a prophage that is deficient in a
major head protein, along with the plasmids carrying for-
eign head protein genes for both wild-type and recombinant
phages [73].
2.4. Exosomes
Exosomes are small (50–100 nm), spherical vesicles man-
ufactured and released by most cells, like B cells [115], T
cells [116], mast cells [117], epithelial cells [118] and Dendritic
Cells (DCs) [119], to facilitate intercellular communication.
These vesicles are of an endosomal origin, which are secreted
in the extracellular milieu following the fusion of late endoso-
mal multivesicular bodies with the plasma membrane [120].
Exosomes have a defined protein composition, which con-
fers specific biological activities contingent on the nature of
the producing cell [121]. In the multivesicular bodies of anti-
gen presenting cells, exogenous antigens are loaded onto MHC
molecules andwhen themultivesicular bodies fusewith the cell
membrane, the MHC molecules are incorporated into the cell
membrane [122]. The internal vesicles are simultaneously re-
leased as extracellular exosomes [123].
Exosomes from antigen presenting cells bear not only MHC
class I and II, but also costimulatory molecules, such as CD54,
CD80 and CD86, and they are enriched in tetraspanin proteins,
like CD63 and CD81 [124,125]. Tetraspanin proteins have been
proposed to have amodulatory role in several different cell pro-
cesses, including adhesion, migration and proliferation [126].
Exosomes have been confirmed to be present in bronchoalve-
olar lavage [127], human plasma [128], malignant effusions
[129,130] and on the surface of follicular dendritic cells [131];
however, their physiological roles in vivo are still unclear. They
have been suggested to participate both in T cell stimula-
tion [42,43] and in tolerance induction [44]. Studies in mice
have demonstrated the potential of exosomes as immunother-
apeutic agents in infections [132], transplantations [133], and
cancer [134–136].
The mechanisms for how exosomes stimulate T cells are un-
known. Some reports indicate that the exosomes from antigen
presenting cells can stimulate T cell clones, on their own [122]
and more efficiently, if the exosomes come from mature den-
dritic cells [42,136]. Other studies confirmed that exosomes
1006 P. Gill / Scientia Iranica, Transactions F: Nanotechnology 20 (2013) 1003–1013require the presence of dendritic cells to efficiently stimulate
T lymphocytes [43,137,138]. Some reports have employed T
cells [43,139], hybridomas [43,136] or clones [122,42,137,138]
when looking at the capability of exosomes to stimulate T cells
in an antigen-specific manner. These studies demonstrate that
exosomes can directly stimulate viral-specific peripheral CD+8 T
cells [140].
Although exosomes express tumor antigens, leading to
their proposed utility as nanovaccines, they also can suppress
T-cell-signaling molecules and induce apoptosis [141]. The first
phase I clinical trial using autologous exosomes has indicated
the feasibility of large-scale exosome production and the safety
of exosome administration [142]. Exosomes manufactured by
dendritic cells are named ‘‘dexosomes’’ and contain essential
components to activate both adaptive and innate immune re-
sponses [143]. For instance, dexosome nanovaccines have been
developed that employ patient-specific dexosomes loadedwith
tumor antigen-derived peptides to treat cancer [144]. The Ex-
osome Display Technology manufactured by Anosys provides
the capability to manipulate exosome composition, and tailor
exosomes, with new desirable characteristics, opening up op-
portunities in the field of recombinant vaccine and monoclonal
antibody preparation [145]. This is gained via generating gene
coding for the chimeric proteins, attaching an exosomeaddress-
ing sequence to antigens or biologically active proteins [146].
The resulting proteins are targeted to the exosomal compart-
ment and released in the extracellular milieu enclosed to ex-
osomes [147]. Exosome research continues to reveal unique
potential that broadens its field of application.
3. Man-made nanocarriers
3.1. Proteosomes
Proteosomes are vaccine delivery vehicles by virtue of their
nanoparticulate nature, forming vesicles and vesicle clusters
comparable to the size of small viruses [148,149]. Proteosome
has been used to describe preparations of the outer membrane
proteins frommicroorganisms [150–154]. Proteosomes are de-
scribed as comparable in size to certain virus particles that
are hydrophobic and safe for human application [155]. Proteo-
somes are said to be useful in formulating vaccines with a va-
riety of proteins and peptides [156,157]. Proteosome vaccine
vesicles and vesicle clusters may range in size from 20 to 800
nm, based on the type and amount of antigen encapsulatedwith
the proteosomes [158]. The hydrophobic nature of the proteo-
some porin proteins also contributes to vaccine delivery capa-
bilities by facilitating interaction of the vaccine nanoparticles
with, and uptake of, the nanovaccines by cells that initiate im-
mune responses [159]. The fact that proteosomes are effective
nasal vaccines is considered to be particularly related to this en-
hanced recognition and uptake afforded by the particulate and
hydrophobic nature of proteosomes [160]. This nanocarrier is
being applied to develop nanovaccines for influenza [35,36] al-
lergies [37], plague [38], Shigellosis [39], respiratory syncytial
virus [40], and AIDS [41].
3.2. SuperFluids
SuperFluids are being developed for nanoencapsulating po-
tent viral antigens in biodegradable polymer nanospheres for
controlled release. These nanocarriers are supercritical, critical,
or near-critical fluids, with or without polar cosolvents [161].Application of SuperFluids reduces the exposure of viral anti-
gens, such as HIV and influenza, to potentially denaturing or-
ganic solvents, such as methylenechloride and ethyl acetate,
and improves the stability of protein antigens in the body at an
ambient temperature for a long time. Therefore, the nanocar-
riers enhance the capability of nanoencapsulated vaccine anti-
gens to induce the production of protective and neutralizing
antibodies [55,56].
This controlled release nanovaccine delivery system has the
capability to deliver different types and combinations of HIV or
influenza vaccine candidates (such as whole inactivated virus
particles, DNA plasmids, and subunit protein antigens) [57–59].
The polymer nanoencapsulation technology will decrease cost
by eliminating unnecessary processing steps, while improving
the manufacturing environment [162]. The nanocarrier tech-
nology is portable, inexpensive, and amenable to large-scale
processing [163].
Several enabling nanotechnologies have been developed,
according to SuperFluids, for the enhanced delivery of nanovac-
cines and nanodrugs, ranging from potent anticancer therapeu-
tics to large recombinant proteins. One of these technologies
is protein nanocarriers [164]. Protein nanocarriers can be gen-
erated without reduction in protein integrity and efficacy in a
solvent-free process, based on a SuperFluids rapid expansion
mechanism for the enhanced drug delivery of protein macro-
molecules. This technology can be applied to the pulmonary
delivery of proteins and polypeptides. It also is used for oral
or depot delivery of vaccine antigens. Another form of these
technologies is polymer nanospheres [165,166]. Biodegradable
polymeric nanospheres can be manufactured utilizing Super-
Fluids technologies for the controlled delivery and release of
proteins through reverse engineering of the rapid expansion
mechanism [167]. This technology can be employed for oral or
depot delivery of proteins and controlled-release adjuvants of
vaccine antigens for infectious diseases [168]. The other gen-
eration of these technologies is phospholipid nanosomes [169].
Phospholipid nanosomes or small uniform liposomes for the en-
hanced delivery of hydrophilic and hydrophobic drugs can be
producedwithout the use of toxic organic solvents, using a sim-
ilar mechanism [170]. This technology can be employed for
intravenous and topical administration of small hydrophilic
nanodrugs, proteins and genes [171].
3.3. Nanobeads
Nanoparticle-based nanobeads serve as nanovaccine fab-
rication and more effective immunization [172]. Although a
number of adjuvants are currently confirmed for use in animal
species, only alum has been widely employed in humans [173].
While it induces strong antibody responses, cell-mediated re-
sponses are often low, and inflammatory reactions at the site
of injection are usual [174]. Immunological characteristics of
a novel nanobead adjuvant have been investigated in a large-
animal sheep model [175]. Contrarily to alum, the antigen co-
valently bound to nanobeads induced substantial cell-mediated
responses, alongwithmoderate humoral responses [60]. No ad-
verse results were recognized at the site of immunization in
the sheep [61]. Thus, nanobead adjuvants in veterinary species
may be useful for the induction of immunity to viral pathogens,
where a cell-mediated response is favorable [62]. These find-
ings also highlight the useful ability of nanobead vaccines for
intracellular pathogens in humans [63].
Nanobeadsmeasure 40 nm [176]. Most adjuvants only stim-
ulate antibodies against a particular disease. Nanobead technol-
ogy gives the immune system a further boost, also producing T
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The size of 40 nm is critical, as it is similar in size to many
viruses, where the nanobeads are taken up abundantly by the
immune system and tricked into manufacturing high levels of
many types of T-cell [178]. Covalently attached peptide to inert
carrier nano-beads can induce both cellular and humoral im-
munity in large outbreed animals, such as sheep [179]. This fact
indicates that combining several peptides in the peptide-nano-
bead based vaccine approach can improve immunogenicity and
may be beneficial when dealingwith a highly variable pathogen
like foot-and-mouth disease virus [180].
3.4. Virosomes
Virosomes were developed from liposomes by combining
liposomes with fusogenic viral envelope proteins [181]. Unlike
viruses, virosomes are not capable of replication but are pure
fusion-active vesicles [182]. Due to the presence of specialized
viral proteins on the surface of virosomes, they can be applied
to the active targeting and delivery of their content at the target
site [183]. Viruses have developed the ability to fuse with cells
during the course of evolution, allowing for release of their
contents directly into the cell [184]. This is because of the
presence of fusogenic proteins on the viral surface that facilitate
this fusion. If these fusogenic viral proteins are reconstituted
on the surface of a liposome, then, the liposome also acquires
the ability to fuse with cells [185]. This is an extremely useful
tool in active transport, because it allows the direct release of
the liposomal contents into the cell. As there is no diffusion
of bioactive material involved, it results in a more effective
delivery. In another words, virosomes are reconstituted viral
envelopes that retain the receptor binding and membrane
fusion activities of the virus from which they are derived [186].
Upon endocytosis, the low pH in the endosomes induces
fusion of the virosomal membrane with the endosomal
membrane, causing the release of the contents of the virosome
into the cytoplasm of the cell [187]. The fusion process is
mediated by hemagglutinin, the major envelope glycoprotein
of the influenza virus [188]. Virosomes can be manufactured
by detergent solubilization of the membrane of an enveloped
virus, sedimentation of the viral nucleocapsid, and subsequent
selective removal of the detergent from the supernatant, to
produce reconstituted membrane vesicles consisting of viral
envelope lipids and glycoproteins [189]. The most common
viruses used in the fabrication of virosomes are: Sendai, Semliki
Forest, influenza, herpes simplex, and vesicular stomatitis
[190–194]. The size and surface characteristics of virosomes
can be measured through microscopic visualization. Almeida
and colleagues published the first report on the generation
of lipid vesicles containing viral spike proteins derived from
the influenza virus [195]. They succeeded in producing
membrane vesicles with spike proteins protruding from the
vesicle surface using preformed liposomes and hemagglutinin
and neuraminidase, purified from the influenza virus [196].
Visualization of these vesicles by electron microscopy revealed
that they very much resembled the native influenza virus.
Consequently, they were called virosomes [197].
Reconstituted virosomes or artificial viral envelopes appear
to be ideally suited as nanovaccine formulations for the deliv-
ery of protein antigens to the cytosol of antigen presenting cells,
and thus, for the introduction of antigenic peptides into the
MHC class I presentation pathway [198]. Cytotoxic T-cell activ-
ity can be induced by immunization of mice with an antigenic
peptide or an entire protein encapsulated in virosomes [51].The action of influenza virosomes is likely to involve both
delivery of the enclosed antigen to the cytosol of antigen pre-
senting cells and the powerful helper activity of the viroso-
mal hemagglutinin. Although the immune responses elicited by
DNA-virosomes are moderate, they are promising and warrant
further research to ultimately develop effective DNA-based vi-
rosomal nanovaccines [199]. The presence of virus proteins not
only allows the liposome to target a particular cell, but also al-
lows it to fuse with the cell, ensuring direct delivery of the in-
corporated material [200].
The key feature of the immunopotentiating reconstituted in-
fluenza virosomes is cytoplasmic delivery of the molecules en-
capsulated in or associatedwith the nanoparticle, as opposed to
plain liposomes being a prerequisite for efficient immune acti-
vation [201]. Two human nanovaccines based on this technol-
ogy (i.e., hepatitis A virus and influenza) have been successfully
transferred to themarket. Several additional candidates are also
under development [202–204]. The excellent immunogenicity,
as well as superior tolerability, of virosomal nanovaccines has
been clinically approved. In the trivalent influenza nanovaccine,
the virosome components (hemagglutinin and neuraminidase),
which are isolated from virus strains yearly recommended by
the World Health Organization, correspond to the nanovaccine
protective antigens [202].
Furthermore, virosomes have been shown to induce cyto-
toxic T cell responses specific to encapsulated peptides. There-
fore, they may also be employed to incorporate other unrelated
antigens in the virosomal membrane; for example, a viroso-
mal hepatitis A virus nanovaccine is currently on the market
[203,204].
Further development of virosomal nanovaccineswill include
the formulation of peptide epitopes (e.g. malaria, and hepatitis
C) [205,206] and approaches based on the use of recombinant
protein [52] or nucleic acid [53]. Because virosomal nanovac-
cines can induce both cellular and humoral responses, these ef-
forts are not limited to prophylactic purposes, but aim also for
therapeutic applications in the field of chronic infectious dis-
eases and cancer [54].
3.5. Liposomes
Liposomes are vesicles of varying size consisting of a spher-
ical lipid bilayer and an aqueous inner compartment that is
produced in vitro [207]. First, liposomes were employed as a
model to study the effect of narcotics on lipid bilayer mem-
branes [208]. Later, the liposomal structures were used as an
immunological adjuvant [209]. Since these early experiments,
liposomes have become an established carrier and delivery ve-
hicle in the field of pharmaco- and immuno-therapy.
Various aspects of immune responses mediated by lipo-
somes in vivo show their promise in the development of
optimized and subunit-defined nanovaccines [210]. The exten-
sive literature demonstrates that liposomes are endocytosed
and they undergo processing through a very well character-
ized endocytic pathway, delivering their contents, including
peptide antigens [211] to lysosomes [212]. Liposomes are a
unique among delivery systems in that they are capable of
modulating the generation of both CD+4 [45] and CD
+
8 [46]
mediated immune responses, and generation of Th1, Th2 or
Th1/Th2 [47] phenotypes, andmay possess the capacity tomod-
ulate a Th1/Th2 switch [48]. The induction of cell-mediated im-
mune responses clearly proposes the occurrence of intracellu-
lar delivery of antigen to antigen presenting cells via the classi-
cal MHC I and MHC II pathways. Additionally, liposomes might
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by CD1 molecules [49]. Liposomes have also been reported to
promote the development of T-cell independent immune re-
sponses [213], and are recognized for their potential to promote
long-term immunity through the development of T-cell mem-
ory [214].
The findings outlined above show the versatility and capa-
bility of liposomes for cell-mediated immunization. However,
the specific mechanisms by which they modulate antigen pre-
sentation remains unclear [215], and their deliverymechanisms
have not been optimized for immunization purposes. It has
been suggested that immunization by the use of liposomeswith
entrapped DNA could circumvent the request for muscle in-
volvement and facilitate [216], instead, the uptake of DNA by
antigen presenting cells infiltrating the site of injection or in
the lymphatics, at the same time protecting DNA from extra-
cellular degradation [217]. Moreover, transfection of antigen
presenting cells with the liposomal DNA and subsequent im-
mune responses to the expressed antigen could be promoted
by the judicious choice of vesicle surface charge, size, and lipid
composition or by the coentrapment of DNA with the plasmids
expressing appropriate cytokines or immuno-stimulatory se-
quences [218].
Procedures have been now developed, by which plasmid
DNA can be quantitatively entrapped into large [219] or
small [220] neutral, anionic, or cationic liposomes that are ca-
pable of transfecting cells in vitrowith varying efficiency [221].
Using liposomes, immunization of inbred or outbred mice by a
variety of routes, including the oral route [222], with cationic
liposomal DNA, led tomuch greater humoral and cell-mediated
immune responses, including cytotoxic T cell [50] immune re-
sponses to the encoded antigen, than those gained with naked
DNA or DNA complexed to preformed similar liposomes. This
approach to genetic immunization mimics the way by which
immunity is acquired in viral infections, where both the viral
DNA and the envelope proteins it encodes contribute to the im-
mune responses against the virus [223]. This technology has
been further advanced by the finding that coating liposomes
containing the DNA and protein nanovaccines with mannose
residues, via incorporation into the bilayers of a mannosylated
lipid, further potentiates immune responses to thenanovaccine,
presumably by the targeting of such liposomes to the mannose
receptors on the surface of antigen presenting cells [224].
4. Nanobacteria
Nanobacteria are novel self-replicating- and mineralizing
agents. The nanobioparticles have been purported to be living
organisms that are 80–500 nm in size [225]. Nanobacteria have
been identified by National Aeronautics and Space Adminis-
tration (NASA) scientists as a potential culprit in kidney stone
formation among astronauts. With the potential for future ex-
ploratory space missions to the Moon and Mars, longer mis-
sions, and exposure to the elements of outer space, health is a
major concern for astronauts [226]. The concept that nanobac-
teria are living organisms is still controversial, because research
into their putative nucleic acid has not been completed yet.
However, researchers have provided additional clues to under-
standing nanobacteria and its link to pathologic calcification-
related diseases [227].
Nanobacteria are, in fact, an abiotic phenomenon [228]. First
reports stated that the investigators could obtain nanobacteria-
like particles from healthy human serum by following a
previously published protocol, but they observed that thesenano-sized organisms were identical to the nanoparticles that
are obtained when CaCO3 precipitates [229]. Further investiga-
tions indicated that varying the levels of CO2 and NaHCO3 in the
growth medium that was used to incubate the human serum
could change the appearance of the nanobacteria-like particles
and, so, it could be concluded that the nanobacteria are CaCO3
precipitates [230]. In another study, the nanobacteria strain
Nanobacterium sp. strain Seralab 901045 was analyzed [231].
This strain was submitted to a comprehensive battery of tests,
and the researchers concluded that there was no evidence
to support the theory that nanobacteria are living organisms,
and instead proposed that they are self-propagating nanopar-
ticles that comprise a fetuin-containing mineral–protein com-
plex [232].
On the other hand, nanobacteria are cytopathic in cells and
invade mammalian cells in a distinctive pathway. Nanobacte-
ria trigger mammalian cells that are not commonly phagocytic
to engulf them, subsequently [233]. The nano-organisms are
one of the agents for cell vacuolization, poor thriving and un-
expected cell lysis, problems generally encountered in mam-
malian cell cultures. Electronmicroscopy and FITC stainingwith
specificmonoclonal antibodies revealed that nanobacteriawere
bound on the surface of the fibroblasts [234]. This means that
nanobacteria were internalized, either by receptor-mediated
endocytosis or in a closely relatedmanner. Fibroblasts indicated
apoptotic abnormalities and death after internalization, if sub-
jected to a high dose of nanobacteria per cell [233,234].
In summary, nanobacteria are non-detectable organisms
with present sterility testing procedures; however, they are de-
tectable with advanced culture and immunoassays. They are
commonly present in serum and blood products and subse-
quently in cell cultures and antigens (such as nanovaccines de-
rived therefrom). Also, they may be present in antibody and
gammaglobulin products. Nanobacteria are a potential risk be-
cause of their cytotoxic properties and capability of infecting
fetuses. Thus, their pathogenicity should be scrutinized [235].
5. Conclusions
Nanobiotechnology in nanomedicine is in its infancy, hav-
ing the potential to change medical research dramatically in
the twenty-first century. Nanocarriers can be employed for
analytical, nanoimaging [236], nanodiagnostic [237–239], nan-
otherapeutic [240], and nanovaccination (Table 1) [241] goals.
Objectives, such as targeting cancer [242], drug delivery [243],
improving cell-material interaction [244], scaffolds for tissue
engineering [245], gene delivery systems [246], and provid-
ing innovative opportunities in the fight against incurable
diseases [247], will improve the use of nanobiotechnologies.
Having more knowledge about nanobiotechnological tools and
techniques [248,249], there has been great progress on rec-
ognizing the function of biological nanostructures and their
interaction and integration with several non-living systems.
However, there are still open issues to be considered, mainly
related to the biocompatibility of the nanomaterials which are
entered into the body [250]. Many novel nano-sized materials
and nanocarriers are expected to be used, with an enormous
positive impact on human health. In fact, the side-effects can
be significantly reduced by delivering the vaccine agents us-
ing nanocarriers. For example, the vision is to improve health
by enhancing the efficacy and safety of vaccination using
nanobiotechnological approaches [251].
P. Gill / Scientia Iranica, Transactions F: Nanotechnology 20 (2013) 1003–1013 1009On the other hand, the safety of nanovaccines is equally
important. This concept has been found to be useful in em-
ploying nanovaccines. However, with nanovaccines, the parti-
cles are cleared slowly over a prolonged time period and this
may induce toxicity [251]; thus, nanobacterial contamination
would be possible. In recent years, some scientists have eval-
uated different nanomaterials with different assays to show
their heterogeneous responses and their activities in life sys-
tems [252]. They also predicted the nanotoxicity of nanomate-
rials and their safety in human studies. Their efforts will help to
speed up nanotoxicological tracking of nanomaterials by apply-
ing high-throughput assays and evaluation acceleration using
nanomaterials for clinical trials, tomanage disorders in the near
future [251,253].
In conclusion, ‘‘Nanobiotechnology’’ will play a key role in
the medicine of tomorrow (i.e., Nanomedicine) providing revo-
lutionary opportunities for therapeutic and protective ways to
improve health and enhance human physical abilities, and en-
able precise and effective modern nanovaccines tailored to the
patient [254].
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